Company Interview / Immugene (ASX: IMU) Investor Presentation

Imugene CEO Leslie Chong highlights significant progress for the company’s cancer treatment pipeline, focusing on the allogeneic chimeric antigen receptor T-cell therapy, Azercell. Chong outlines Azercell’s ability to serve patients with blood cancers, particularly those who have failed multiple lines of therapy, including approved autologous Car-T treatments. Unlike traditional autologous Car-T therapies, which require a lengthy and highly personalised process, Azercell employs healthy donor T cells, enabling rapid, off-the-shelf administration at major medical sites across the US and Australia.

Chong reports that Azercell’s recent clinical trial updates show notable outcomes, with overall response rates climbing from 57% in February to an impressive 81% in September among late-stage patients. Some patients have experienced complete responses lasting up to 18 months, representing a meaningful advance for those with limited options. Azercell is contrasted with existing therapies such as Yescarta, Kymriah, and Breyanzi, all targeting CD19 and approved for earlier line patients, but Chong stresses that Imugene’s data apply to heavily pre-treated populations.

Looking ahead, Chong indicates the company is preparing for a pivotal FDA meeting at the end of the year and anticipates moving into registration studies by late 2025. Imugene aims to commercialise Azercell through partnerships, with ongoing discussions and potential for licensing deals.

 *The information contained in this event is general in nature and is not intended as advice. Before acting on information you've seen or heard at this event, you should seek professional financial advice that takes into account your personal circumstances. 

You should be aware that companies presenting do so under commercial agreement with AUSBIZ CAPITAL PTY LTD